Connor, Clark & Lunn Investment Management (CC&L)’s Rhythm Pharmaceuticals RYTM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.1M	Sell	135,867 -15,975	-11%	-$1.44M	0.03%	438
2026 Q1	$13.2M	Buy	151,842 +2,469	+2%	+$240K	0.03%	416
2025 Q4	$16M	Buy	149,373 +28,113	+23%	+$2.98M	0.04%	335
2025 Q3	$12.2M	Buy	121,260 +6,142	+5%	+$570K	0.04%	369
2025 Q2	$7.27M	Buy	115,118 +64,561	+128%	+$3.95M	0.03%	484
2025 Q1	$2.68M	Buy	50,557 +44,468	+730%	+$2.47M	0.01%	659
2024 Q4	$341K	Buy	+6,089	New	+$336K	﹤0.01%	1235
2024 Q3	–	Sell	-9,340	Closed	-$384K	–	1617
2024 Q2	$384K	Sell	9,340 -335	-3%	-$13.4K	﹤0.01%	1121
2024 Q1	$419K	Sell	9,675 -55,869	-85%	-$2.45M	﹤0.01%	1175
2023 Q4	$3.01M	Sell	65,544 -66,118	-50%	-$2.09M	0.01%	564
2023 Q3	$3.02M	Buy	131,662 +73,543	+127%	+$1.65M	0.02%	513
2023 Q2	$958K	Buy	+58,119	New	+$1.05M	﹤0.01%	807
2022 Q3	–	Sell	-11,225	Closed	-$47K	–	1233
2022 Q2	$47K	Buy	+11,225	New	+$61.4K	﹤0.01%	1008

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RYTM Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Rhythm Pharmaceuticals (RYTM) stake by 11% in Q2 2026, selling an estimated $1.44M and leaving 135,867 shares worth $15.1M. The position accounts for 0.03% of the portfolio, ranked #438.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RYTM in Q2 2022 and has held it in 13 quarters since. The position peaked at $16M in Q4 2025. 302 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 135,867 shares of Rhythm Pharmaceuticals worth $15.1M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 15,975 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
Rhythm Pharmaceuticals made up 0.03% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #438 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Rhythm Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Rhythm Pharmaceuticals position peaked at $16M in Q4 2025.
302 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.